Seelos Therapeutics, Inc. (SEEL) financial statements (2021 and earlier)

Company profile

Business Address 300 PARK AVENUE
NEW YORK, NY 10017
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1610462411
Cash and cash equivalents1610462411
Restricted cash and investments     00
Receivables    111
Inventory, net of allowances, customer advances and progress billings    100
Inventory    100
Other undisclosed current assets2100011
Total current assets:1711474613
Noncurrent Assets
Property, plant and equipment  00111
Other noncurrent assets  00000
Total noncurrent assets:  00122
TOTAL ASSETS:1711475815
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4312567
Accounts payable2100121
Accrued liabilities2211335
Employee-related liabilities  01111
Debt2   790
Deferred compensation liability      0
Derivative instruments and hedges, liabilities11     
Accrued environmental loss contingencies      0
Disposal group, including discontinued operation  0    
Deferred revenue and credits0 00
Other undisclosed current liabilities07    (0)
Total current liabilities:7111211167
Noncurrent Liabilities
Long-term debt and lease obligation7     5
Long-term debt, excluding current maturities7     5
Capital lease obligations    0
Liabilities, other than long-term debt  01122
Deferred revenue and credits   1
Deferred compensation liability, classified      0
Other liabilities  00000
Derivative instruments and hedges, liabilities   112 
Other undisclosed noncurrent liabilities00    (0)
Total noncurrent liabilities:7001126
Total liabilities:151112121813
Stockholders' equity
Stockholders' equity attributable to parent3(0)34(8)(10)2
Common stock0000000
Additional paid in capital7856328320309299292
Accumulated deficit(75)(56)(325)(316)(316)(309)(290)
Total stockholders' equity:3(0)34(8)(10)2
TOTAL LIABILITIES AND EQUITY:1711475815

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues00 1659
Revenue, net1659
Net investment income00     
Cost of revenue
(Cost of Goods and Services Sold)
    (4)(1)(1)
Gross profit:00 1248
Operating expenses(19)(30)(9)(11)(15)(25)(31)
Other undisclosed operating loss(0)  (1)   
Operating loss:(19)(30)(9)(11)(13)(21)(23)
Nonoperating income (expense)(0)(22)(0)(1)620
Investment income, nonoperating      1
Gain on contract termination      1
Other nonoperating income (expense)  00(0)(0)1
Interest and debt expense(0)(0) (0)(1)(1)(0)
Loss from continuing operations before income taxes:(19)(51)(9)(12)(8)(20)(23)
Other undisclosed income from continuing operations      0
Loss from continuing operations:(19)(51)(9)(12)(8)(20)(22)
Income from discontinued operations      1
Net loss:(19)(51)(9)(12)(8)(20)(22)
Other undisclosed net income (loss) attributable to parent00(0)1211 
Net income (loss) available to common stockholders, diluted:(19)(51)(9)0(7)(19)(22)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(19)(51)(9)(12)(8)(20)(22)
Comprehensive loss, net of tax, attributable to parent:(19)(51)(9)(12)(8)(20)(22)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: